|
|
|
|
Dude
SFN Die Hard
USA
6891 Posts |
 Posted - 02/21/2008 : 00:28:19
|
Interesting discovery, and maybe a new weapon in the arsenal to use against drug resistant staph infections.
The most interesting part, this compound (referenced as BPH-652 in the article) is already in phase three clinical trials under the brand name "lapaquistat". It is being tested for use against high cholesterol.
Not much data on the current trial, but the phase two trial didn't indicate any safety issues or side effect rates beyond those already associated with the current statin anti-cholesterol drugs.
This may be a bit of good news in our fight against drug resistant bacteria. There are some very very nasty strains of staph aureus out there.
|
Ignorance is preferable to error; and he is less remote from the truth who believes nothing, than he who believes what is wrong.
-- Thomas Jefferson
"god :: the last refuge of a man with no answers and no argument." - G. Carlin
Hope, n.
The handmaiden of desperation; the opiate of despair; the illegible signpost on the road to perdition. ~~ da filth |
|
|
|
Dude
SFN Die Hard
USA
6891 Posts |
Posted - 02/21/2008 : 00:45:03 [Permalink]
|
Ok, Lapaquistat is not BPH-652. (lapaquistat is TAK-475)
My error. But it is still in the same group of drugs (squalene synthase inhibitors).
Both compounds are, or have been, in human clinical trials.
Very interesting.
I'm sure we'll be hearing more about this before long.
|
Ignorance is preferable to error; and he is less remote from the truth who believes nothing, than he who believes what is wrong.
-- Thomas Jefferson
"god :: the last refuge of a man with no answers and no argument." - G. Carlin
Hope, n.
The handmaiden of desperation; the opiate of despair; the illegible signpost on the road to perdition. ~~ da filth |
|
| Edited by - Dude on 02/21/2008 00:46:52 |
 |
|
|
 |
|
|
|
MRSA
